Jubilant Life Sciences grants an exclusive license to Frazier
Healthcare Partners newly launch company: Lengo Therapeutics
Frazier Healthcare Partners Launches Lengo Therapeutics
New Company to Discover and Develop Precision Oncology Medicines
MENLO PARK, Calif. & BANGALORE, India--(BUSINESS WIRE)--Frazier Healthcare Partners (“Frazier”) today
announced the launch of Lengo Therapeutics, Inc. (“Lengo”), a biopharmaceutical company focused on thediscovery and development of novel treatments targeting driver mutations in oncology.
“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of ourearly-stage companies”“Lengo emerged from discussions at Frazier and among a highly experienced group of oncology researchers,including Frazier Senior Advisors Roger Ulrich, Ph.D., Jim Bristol, Ph.D., Michael Gallatin, Ph.D. and Bruce
Roth, Ph.D., who helped identify several mutations in cancers that we felt were not well addressed byexisting therapeutics,” said Tracy Saxton, Ph.D., CEO of Lengo. ”We were fortunate to identify novel
chemical matter discovered at Jubilant to address some of these mutations of interest.”
Jubilant Life Sciences Ltd (“Jubilant”) has granted an exclusive license to Lengo for the worldwide
development and commercialization of a portfolio of novel chemistry against undisclosed oncology targets.
In connection with the license, Lengo has completed a $15 million Series A financing round from Frazier.

DJubilant and Frazier have been working together on multiple discovery-stage companies since 2016, startingwith Mavupharma which was acquired by AbbVie in 2019.
“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of ourearly-stage companies,” said Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team. “We areexcited to advance the assets we have licensed at Lengo to the clinic as quickly as possible.”DD“We are pleased to be strengthening our ties with Frazier Healthcare Partners,” said Shyam Bhartia and Hari
Bhartia, founders of Jubilant. “We welcome the addition of Lengo to the pipeline of companies we areworking on together in drug discovery.”About Jubilant Life Sciences
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in
Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Drug
Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through JubilantBiosys Limited & Jubilant Chemsys Limited and Proprietary Drug Discovery business through Jubilant
Therapeutics. Jubilant Life Sciences Limited has a team of around 7,700 multicultural people across theglobe and is committed to deliver value to its customers across over 100 countries. The Company is wellrecognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For
more information: www.jubl.com

About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital tohealthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200companies, with investment types ranging from company creation and venture capital to buyouts ofprofitable lower-middle market companies. The firm’s Life Sciences team invests in therapeutics and relatedareas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and
Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information:
http://www.frazierhealthcare.com.

This article was posted by businesswire.com on May 12, 2020

DDD